Study S002307

A Phase 2 Randomised Controlled Study to Investigate the Efficacy and Safety of Subcutaneously Administered PG-102 for 24 Weeks Compared With Placebo and Open-Label Semaglutide in Patients With Type 2 Diabetes Mellitus

ClinicalTrials.gov record

Registration

Registration: NCT07187856
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE2
Masking: DOUBLE
Status: NOT_YET_RECRUITING
Enrollment: 80
Start: 2026-01
Primary completion: 2026-09
Lead sponsor: ProGen. Co., Ltd.
Conditions: Type 2 Diabetes Mellitus (T2DM)
Interventions: DRUG:PG-102; DRUG:Placebo; DRUG:Semaglutide
Results posted: FALSE

Registered primary outcomes

Absolute change in HbA1c From Baseline at Week 24 [24 weeks]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.